DailyIQ
|
Sector:HealthcareAll sectors
Last updated 7 minutes ago

BMY·Bristol-Myers Squibb Company

$.
+. (+.%)
Pre-Market
High
$61.09
Open
$60.55
Market Cap
121.79B
52W High
$62.89
Low
$60.41
P. Close
$60.30
P/E
20.38
52W Low
$42.52
Fwd P/E
18.86
DailyIQ Est.
$63.58
Technical Score (1D)
82
BUY
News Sentiment
83
BULLISH
Bristol Myers Squibb’s FDA approval of the mezigdomide‑carfilzomib‑dexamethasone combination for relapsed or refractory multiple myeloma marks a significant expansion of its oncology portfolio, potentially adding a new revenue stream in the next 1–10 trading days. The approval follows a Phase 3 trial that demonstrated meaningful progression‑free survival gains, giving the mandate to launch pricing and reimbursement negotiations that could drive early revenue. Traders should watch the pricing strategy and payer uptake, as these will shape the therapy’s commercial trajectory. BMY’s track record of consistently beating earnings estimates adds further upside potential, and current guidance suggests the company may continue to outperform expectations. The upcoming earnings release will confirm whether the guidance holds and will likely provide updates on other pipeline developments, which could reinforce the earnings outlook. Investor interest on Zacks.com has risen, indicating growing market attention that could amplify volatility around key corporate events. Watch for any strategic partnership announcements or R&D milestones that could accelerate the commercialization of mezigdomide or other pipeline assets. On a second‑order level, a stronger oncology pipeline may increase demand for specialty manufacturing inputs and support broader biotech sector activity. Finally, keep an eye on regulatory decisions for BMY’s other drug candidates, as additional approvals or setbacks could materially alter the company’s growth narrative.
Earnings Summary
Bristol‑Myers Squibb (BMY) is a global biopharmaceutical company that develops and markets innovative medicines across oncology, hematology, immunology, and cardiovascular disease, with flagship products such as Eliquis, Opdivo, and Orencia. Operating in the healthcare sector, the firm’s earnings are largely driven by drug sales and pipeline approvals. In the most recent two quarters, BMY reported EPS of $1.58 in Q1 2026 and $1.63 in Q3 2025, both exceeding analyst expectations of $1.42 and $1.52, respectively, while revenue rose to $11.489 billion from $12.502 billion, reflecting a 9.5 % YoY decline in Q1 2026 versus Q4 2025; the company has consistently beat estimates in all eight quarters reported, with EPS surpassing forecasts in every period. Historically, BMY’s top‑line has shown modest volatility, with revenue fluctuating between $11.2 billion and $12.5 billion over the past year, yet the firm’s earnings beat record and steady fee‑income from established products support a resilient profitability profile. Recent regulatory news announced FDA approval of the mezigdomide‑carfilzomib‑dexamethasone combination for relapsed or refractory multiple myeloma, marking a significant expansion of its oncology portfolio; this milestone could add a new revenue stream in the near term, contingent on pricing and payer uptake. Investors should watch for guidance on launch timing, pricing strategy, and reimbursement plans for the new therapy, as well as updates on other pipeline candidates, because these factors will shape BMY’s future earnings trajectory and influence market sentiment toward its growth prospects.

EPS

EstBeatMiss
$1.00$1.22$1.45$1.68$1.90Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.59 - -
Q1'26$1.42$1.58+11.1%
Q4'25$1.13$1.26+11.9%
Q3'25$1.52$1.63+7.6%
Q2'25$1.10$1.46+32.6%
Q1'25$1.50$1.80+19.9%

Revenue

EstBeatMiss
$10.7B$11.2B$11.7B$12.2B$12.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$11.8B - -
Q1'26$10.9B$11.5B+5.2%
Q4'25$12.4B$12.5B+0.8%
Q3'25 - $12.2B -
Q2'25 - $12.3B -
Q1'25 - $11.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BMY Stock Snapshot

BMY is currently trading at $60.99, giving Bristol-Myers Squibb Company a market cap of 121.79B and a P/E ratio of 20.4. Today's range spans $60.41–$61.09, with shares opening at $60.55 and moving up $0.69 (1.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 83/100.

Over the past year BMY has traded between $42.52 and $62.89 - the current price is +43.4% off the 52-week low and -3.0% from the high. 36 analysts cover the stock with a Hold consensus and a mean 12-month target of $62.96 (range $40.00–$75.00), implying upside of +3.2%.

The bullish case for BMY is built on complementary signals: 82/100 technical score, BUY designation, and bullish sentiment at 83/100. At $60.99 (near 52-week highs within $42.52–$62.89), the stock is at a capitalization - 121.79B - where active managers can build meaningful positions without moving the market. (P/E: 20.4) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Healthcare.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (83/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $60.99 (near 52-week highs), BMY's position within the $42.52–$62.89 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.